Currently, chronic disease prevention and control in China has entered a new phase characterized by precision and intelligent development, presenting dual opportunities of digital transformation and personalized healthcare for the management of the "three highs" comorbidities. This symposium, aligned with the evolving needs of healthcare development in the new era, focused on exploring the application prospects of emerging technologies such as artificial intelligence and big data in early screening, risk prediction, and remote management of metabolic diseases, with the aim of establishing an intelligent prevention and control system based on real-world evidence. Special attention was given to the pivotal role of primary healthcare institutions in managing these comorbidities, with in-depth analysis of exemplary regional prevention and treatment cases to distill replicable models of tiered diagnosis and treatment as well as innovative service pathways.

       As the fourth installment in this series, the event built upon the academic legacy of previous conferences while placing greater emphasis on integrating clinical needs with technological innovation. By fostering a multi-stakeholder dialogue platform encompassing industry, academia, research, and clinical practice, it facilitated the development and translational application of intelligent medical products. The symposium provided novel insights for constructing a chronic disease management system covering the entire life cycle, contributing to the strategic shift from disease treatment to health management and injecting new momentum into advancing the Healthy China initiative.